Chronic atrophic gastritis
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Zhejiang University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients meeting the diagnostic criteria of chronic atrophic gastritis (Olga stage II and above); 2. Patients aged from 18 to 65 years old (including 18 and 65 years old) are not limited in gender; 3. The patients who voluntarily participate in this clinical trial should have informed consent and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with peptic ulcer, gastroesophageal reflux disease and other diseases requiring PPI treatment; 2. Patients with high grade intraepithelial neoplasia of gastric mucosa or suspected malignant change by pathological diagnosis; 3. HP positive patients and those who have received anti HP treatment and related treatment in the past four weeks; 4. Drug history: Taking the following drugs within one month before specimen collection: (1) Antibiotics (oral, intramuscular and intravenous); (2) Microecological agents (probiotics, prebiotics, synbiotics, etc.); (3) Various drugs (proton pump inhibitors and H2 receptor antagonists, etc.) that inhibit gastric acid secretion; (4) Cytokines, immunosuppressants and cytotoxic agents, etc; (5) Hormones; (6) Other drugs affecting gastric flora; 5. Patients with abnormal renal function and clinical significance, liver function ALT >= 2 times the upper limit of normal reference value; 6. Patients with serious primary heart, liver, kidney, lung, blood and nervous system diseases; 7. Patients with mental retardation or psychosis; 8. Patients with suspected or true history of alcohol or drug abuse; 9. Pregnant and lactating women or women and men with family planning within one year; 10. Patients with known or suspected allergic history to the test drug and its excipients; 11. Patients who have participated in other clinical trials in recent 3 months; 12. Patients considered unsuitable by the researchers to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histopathology of gastric mucosal atrophy; | — |
Secondary
| Measure | Time frame |
|---|---|
| OLGA;Grading of endoscopic gastritis;Main clinical symptoms; | — |
Countries
China
Contacts
Public ContactLyu Bin
The Ethics Committee of the First Affiliated Hospital of Zhejiang University of Chinese Medicine
Outcome results
None listed